Skip to main content
Clinical Trials/NCT00890799
NCT00890799
Completed
Not Applicable

Clinical Evaluation of Transcatheter Closure and Surgery of Perimembranous Ventricular Septal Defects

Xijing Hospital0 sites200 target enrollmentJune 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ventricular Septal Defects
Sponsor
Xijing Hospital
Enrollment
200
Primary Endpoint
Major adverse events
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to investigate effectiveness and safety of transcatheter closure of perimembranous ventricular septal defects.

Detailed Description

Perimembranous Ventricular septal defect (VSD) is the most common congenital cardiac malformation and constitutes over 20% of all congenital cardiac disease. Though conventional surgery for VSD is a widely accepted procedure with minimal operative mortality, it carries a small but definite risk of morbidity and mortality associated with cardiopulmonary bypass and surgical closure. The newly appeared transcatheter device closure technique provides an alternative to surgical closure. However, the mid-to-long term effects of this technique using occluders is not clear. The aim of this study was to evaluate the safety and effectiveness of transcatheter closure of perimembranous ventricular septal defects using septal occluders.

Registry
clinicaltrials.gov
Start Date
June 2007
End Date
July 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Xijing Hospital
Responsible Party
Principal Investigator
Principal Investigator

Jian Yang

Dr Jian Yang

Xijing Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients with ventricular septal defects eligible for transcatheter closure.

Exclusion Criteria

  • Patients less than 2 years old. Patients not suitable for transcatheter closure. Patients comorbid with other diseases.

Outcomes

Primary Outcomes

Major adverse events

Time Frame: till study end

Major adverse events included but were not limited to death during or after the procedure because of complications of the procedure,cAVB requiring pacemaker implantation, thromboembolism, and new-onset valvular regurgitation requiring surgical repair.

Secondary Outcomes

  • Minor adverse events(Till study end)

Similar Trials